Beverly Keseling, (retired) manufacturing manager at BDP, studies PVSRIPO on an inverted microscope. 

FREDERICK, Md. -- The development of a modified poliovirus to treat glioblastoma, a deadly form of brain cancer, is one of the latest examples of the Frederick National Laboratory for Cancer Research stepping in to fill a critical need that few others could meet with developing and manufacturing novel biological agents for early-phase clinical trials.